Spesolimab
3rd May 2019
Unassigned
New Medicines
Ulcerative colitis (UC) in patients who have failed previously biologic therapy
Information
New molecular entity
Boehringer Ingelheim
Boehringer Ingelheim
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
A humanised monoclonal antibody, targeting interleukin 36 (IL-36) receptor
Ulcerative colitis is the most common type of inflammatory disease of the bowel. It has an incidence in the UK of approximately 10 per 100,000 people annually and a prevalence of approximately 240 per 100,000 [1]. ·
Ulcerative colitis (UC) in patients who have failed previously biologic therapy
Subcutaneous and
Intravenous